LYEL
Lyell Immunopharma, Inc.
Key Financials
Operating Income
$-269404000
↑ 24.9%
Net Income
$-274448000
↑ 20.0%
Revenue
$36000
↓ 41.0%
Total Assets
$340.1M
↓ 30.7%
Total Liabilities
$91.8M
↓ 15.0%
EPS (Diluted)
$-16.06
↓ 1126.0%
Cash & Equivalents
$60.2M
↓ 43.0%
Shareholders' Equity
$248.2M
↓ 35.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/1/2026 | View on SEC |
| 4 | 6/18/2026 | View on SEC |
| SCHEDULE 13G/A | 6/18/2026 | View on SEC |
| 3 | 6/18/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 8-K | 6/15/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LYEL |
| Company Name | Lyell Immunopharma, Inc. |
| CIK | 1806952 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650 695-0677 |